Chronic myeloid leukemia (CML) is a type of blood cancer that originates in the bone marrow. Since CML patients are treated with specific drugs, they approach a normal life expectancy. The two most important factors that ensure treatment success are monitoring of disease progression and medication compliance. Both factors are still suboptimal. The CMyLife platform aims to improve the care of CML patients and to increase patient empowerment. This gives patients a better quality of life with more remote care (from home). This thesis focused on research on the implementation, evaluation and improvement of the CMyLife platform. Results show what important factors are to take into account when implementing such a platform. Results also show that the platform is of added value in improving the care of CML patients and that there is still room for improvement.
Lynn Verweij (1995), obtained her Master's degree in Biomedical sciences at the Radboud University in Nijmegen, in 2020. Subsequently, Lynn started her PhD trajectory at the department of haematology of Radboudumc. After finishing her PhD, Lynn continues working on the CMyLife projects at A.T. TWINTEY, the company collaborating with Radboudumc to improve the care of patients with haematological diseases and create sustainable change in health care.